The German Cancer Consortium (DKTK – Deutsches Konsortium für Translationale Krebsforschung) was established in 2012 and is funded by the German Ministry of Research and Education (BMBF) and the Federal States of each DKTK partner site. DKTK is one out of six German Centers for Health Research (DZGs) that were founded to foster research environments for performing clinically–focused research and for fighting widespread diseases. It brings together its core center, the German Cancer Research Center (DKFZ) in Heidelberg, with some of the strongest university hospitals and cancer research institutions across Germany: Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Main, Freiburg, München and Tübingen. The result is a unique network of the DKTK partner institutions which will not only improve cancer research across the country, but will also bring Germany to the forefront of cancer research internationally.
The main focus of the DKTK is translational cancer research by developing customized approaches for better patient care and therefore the transfer of research results from the laboratory into clinical practice in one combined effort (“from bench to the bedside”).
Following interdisciplinary and translational research programs and platforms are part of DKTK:
Program “Exploitation of Oncogenic Mechanisms”
Program “Molecular Diagnostics, Early Detection and Biomarker Development”
Program “Molecularly Targeted Therapy”
Program “Cancer Immunotherapy”
Program “Radiation Oncology and Imaging”
Following interdisciplinary and translational research platforms are part of DKTK:
“Clinical Communication Platform”
“Genome Sequencing and Proteome Analysis Platform”
“School of Oncology” Platform
Please find here further information to DKTK: www.dktk.org
